# Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)

> **NCT04478448** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Flupirava
- **DRUG:** Avigan

## Key facts

- **NCT ID:** NCT04478448
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-13
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-08-26
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478448, "Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04478448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*